Alcohol Use Disorder Market to Witness Positive Growth at a CAGR of 8.8% by 2032 | DelveInsight

News provided by

Sep 28, 2022, 11:30 ET

The alcohol-use disorder market size shall grow during the forecast period (2022─2032) owing to the launch of upcoming therapies, high prevalence of alcohol use disorder, advances in pharmacological treatment, personalized treatment approach, advances in animal models of an alcohol use disorder, and others during the forecast period (2022─2032).

LAS VEGAS, Sept. 28, 2022 /PRNewswire/ --DelveInsight's Alcohol Use Disorder Market Insights report includes a comprehensive understanding of current treatment practices, alcohol use disorder emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU5 (the United Kingdom, Italy, Spain, France, and Germany), Japan].

Key Takeaways from the Alcohol Use Disorder Market Report

As per DelveInsight analysis, the alcohol use disorder market size in the 7MM was approximately USD 564 million in 2021.
As per the estimates, the total alcohol use disorder 12-month diagnosed prevalent cases in the 7MM were approximately 25 million in 2021.
Leading alcohol use disorder companies such as Alkermes, Lundbeck, Otsuka Pharmaceuticals, Adial Pharmaceuticals, MediciNova, Corcept Therapeutics, Astellas Pharma, Bioprojet, and others are developing novel alcohol use disorder drugs that can be available in the alcohol use disorder market in the upcoming years.
The alcohol use disorder therapies in the pipeline include AD04 (ondansetron), MN-166 (ibudilast), CORT 118335 (Miricorilant/mifepristone), ASP 8062, BP1.3656, OPNT002, ALKS 3831, DCR-AUD, Zulresso/brexanolone, BXCL501/dexmedetomidine, PT150, and others.
The alcohol use disorder market is expected to grow due to factors such as expected approval of emerging therapies and the increasingly diagnosed prevalent population of AUD in the 7MM.

Discover which therapies are expected to grab the major alcohol use disorder market share @Alcohol Use Disorder Market Report

Alcohol Use Disorder Overview

Alcohol use disorder (AUD) is one of the most common substance use disorders, characterized by excessive, uncontrollable drinking that has a physical, emotional, and social impact on the individual. Based on the number of symptoms experienced by an individual, it can be classified as mild, moderate, or severe. A person suffering from alcohol use disorder may experience both intoxication and withdrawal alcohol use disorder symptoms such as mood swings, poor judgment, slurred speech, attention or memory problems, poor coordination, sweating, rapid heartbeat, hand tremors, seizures, and so on.

Alcohol use disorder has multiple causes, including genetic, physiological, psychological, and social factors. Healthcare professionals use the Diagnostic and Statistical Manual of Mental Disorders (DSM-V) criteria to diagnose and assess the severity of AUD. At least two of the 11 DSM-V diagnostic criteria must be present to confirm the alcohol use disorder diagnosis.

Alcohol Use Disorder Epidemiology Segmentation

DelveInsight estimates that there were approximately 25 million 12-month diagnosed prevalent cases of alcohol use disorder in the 7MM in 2021.

Among the EU5 countries, Germany had the highest number of alcohol use disorder incident cases in 2021.

The alcohol use disorder market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

12-month Diagnosed Prevalent Cases of AUD
Gender-specific Diagnosed Prevalent Cases of AUD
Type-specific Diagnosed Prevalent Cases of AUD

Download the report to understand which factors are driving alcohol use disorder epidemiology trends @Alcohol Use Disorder Epidemiological Insights

Alcohol Use Disorder Treatment Market

The primary goal of alcohol use disorder treatment is either total abstinence or a reduction in heavy drinking (harm reduction), which serves as a proxy marker for harmful alcohol-related psychosocial consequences. Although there is some debate about which goal of alcohol use disorder treatment is preferable, both options have advantages. Psychosocial intervention is the cornerstone of alcohol use disorder treatment. Unfortunately, the relapse rate with psychosocial intervention alone is higher than when combined with pharmacotherapy.

Currently, there are four US FDA-approved drugs for alcohol use disorder treatment. These medications are Acamprosate, ANTABUSE (disulfiram), REVIA (oral naltrexone), and VIVITROL (extended-release injectable naltrexone). Most of these were approved over a decade ago and require abstinence before starting therapy.

Some drugs, such as BACLOCUR (baclofen), a GABAB agonist in France, sodium oxybate (SMO) or gamma-hydroxybutyric acid (GHB) in Italy and Austria, are also approved for alcohol use disorder treatment. Off-label and generic products for alcohol use disorder include gabapentin, varenicline, benzodiazepines, memantine, ondansetron, aripiprazole, and suvorexants such as Topiramate (TOPAMAX), Gabapentin, Benzodiazepines, Memantine, Ondansetron (ZOFRAN), and others. TOPAMAX (topiramate) is even recommended for alcohol use disorder treatment by the National Institute on Alcohol Abuse and Alcoholism.

To know more about alcohol use disorder treatment options, visit @New Treatment for Alcohol Use Disorder

Alcohol Use Disorder Pipeline Therapies and Key Companies

AD04 (ondansetron): Adial Pharmaceuticals
MN-166 (ibudilast): MediciNova
CORT 118335 (Miricorilant) (mifepristone): Corcept Therapeutics
ASP 8062: Astellas Pharma
BP1.3656: Bioprojet

Learn more about the FDA-approved drugs for alcohol use disorder treatment @Drugs for Alcohol Use Disorder Treatment

Alcohol Use Disorder Market Dynamics

Despite the high prevalence of alcohol use disorder and its associated negative effects, current alcohol use disorder treatment has had limited success in randomized controlled trials. Furthermore, the significant heterogeneity of alcohol use disorder patients makes developing a single drug capable of treating alcohol use disorder patients as a whole particularly difficult. The requirement for abstinence and the associated social stigma also impact alcohol use disorder treatment compliance. Adial Pharmaceuticals, Corcept Therapeutics, Astellas Pharma, MediciNova, Novo Nordisk, Alkermes, BioXcel Therapeutics, Opiant Pharmaceuticals, Bioprojet, and Pop Test Oncology LLC, are developing therapies to address the unmet need in the alcohol use disorder market. A strong pipeline keeps the possibility of a transformative therapy and a strong alcohol use disorder market in the near future.

Moreover, efforts are being made to develop personalized medicines for alcohol use disorder to better tailor treatments to individuals with varying alcohol use disorder manifestations. Biomarker advancements offer hope for more sensitive and specific aids in diagnosis and improved monitoring of alcohol use disorder. Furthermore, companies have a window of opportunity in the alcohol use disorder market to conduct trials evaluating safer therapies with patient-convenient doses at low cost, which can improve treatment compliance and adherence. In addition, key players can use the knowledge gained from recent advances in understanding pathobiological pathways in alcohol use disorder in clinical practice to evaluate potential drugs with novel targets in the alcohol use disorder market.

However, certain factors hamper the growth of the alcohol use disorder market. The most common treatments for alcohol use disorder aim to achieve abstinence, and typical treatments include psychological and social interventions. Due to factors such as stigma and gender barriers, underdiagnosis and under-treatment remain prevalent. Furthermore, the expiration of current therapies' patents, combined with the simultaneous approval of their generics, is responsible for dampening the growth of the alcohol use disorder market and revenue generation of these drugs. Moreover, because of the change in alcohol use disorder diagnostic criteria from DSM-IV to DSM-V, country-specific epidemiologic data on diagnosis, severity, and treatment are scarce and thus limiting the alcohol use disorder market growth.

Report Metrics	Details
Study Period	2019–2032
Coverage	7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Base Year	2021
Market CAGR	8.8 %
Market SIze in 2021	USD 5.64 Million
Key Alcohol Use Disorder Companies	Alkermes, Lundbeck, Otsuka Pharmaceuticals, Adial Pharmaceuticals, MediciNova, Corcept Therapeutics, Astellas Pharma, Bioprojet, and others
Key Alcohol Use Disorder Therapies	AD04 (ondansetron), MN-166 (ibudilast), CORT 118335 (Miricorilant/mifepristone), ASP 8062, BP1.3656, OPNT002, ALKS 3831, DCR-AUD, Zulresso/brexanolone, BXCL501/dexmedetomidine, PT150, and others

Scope of the Alcohol Use Disorder Market Report

Therapeutic Assessment: Alcohol Use Disorder current marketed and emerging therapies
Alcohol Use Disorder Market Dynamics: Alcohol Use Disorder market drivers and barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Unmet Needs, KOL's views, Analyst's views, Alcohol Use Disorder Market Access and Reimbursement

Discover more about drugs for alcohol use disorder in development @Alcohol Use Disorder Clinical Trials

Table of Contents

1.	Alcohol Use Disorder Market Key Insights
2.	Alcohol Use Disorder Market Report Introduction
3.	Alcohol Use Disorder Market Overview at a Glance
4.	Alcohol Use Disorder Market Executive Summary
5.	Disease Background and Overview
6.	Alcohol Use Disorder Treatment and Management
7.	Alcohol Use Disorder Epidemiology and Patient Population
8.	Patient Journey
9.	Alcohol Use Disorder Marketed Drugs
10.	Alcohol Use Disorder Emerging Drugs
11.	Seven Major Alcohol Use Disorder Market Analysis
12.	Alcohol Use Disorder Market Outlook
13.	Potential of Current and Emerging Therapies
14.	KOL Views
15.	Alcohol Use Disorder Market Drivers
16.	Alcohol Use Disorder Market Barriers
17.	Unmet Needs
18.	SWOT Analysis
19.	Appendix
20.	DelveInsight Capabilities
21.	Disclaimer
22.	About DelveInsight

Alcohol Use Disorder Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, and the alcohol use disorder epidemiology trends.

Alcohol Use Disorder Pipeline

Alcohol Use Disorder Pipeline Insight – 2022 report provides comprehensive insights about the pipeline landscape, including clinical and non-clinical stage products, and the key alcohol use disorder companies, including Adial Pharmaceuticals, MediciNova, Corcept Therapeutics, Astellas Pharma, among others.

Alcoholic Hepatitis Market

Alcoholic Hepatitis Market Insight, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key recurrent or alcoholic hepatitis companies, including Durect, Novartis, Immunemed, among others.

Alcohol Addiction Pipeline

Alcohol Addiction Pipeline Insight – 2022 report provides comprehensive insights about the pipeline landscape, including clinical and non-clinical stage products, and the key alcohol addiction companies, including Kontigo Care AB, Bankole Johnson, Alkermes, Inc., among others.

Alcoholic Hepatitis Pipeline

Alcoholic Hepatitis Pipeline Insight – 2022 report provides comprehensive insights about the pipeline landscape, including clinical and non-clinical stage products, and the key alcoholic hepatitis companies, including Durect, Novartis, Immunemed, among others.

Alcohol Addiction Epidemiology

Alcohol Addiction Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the alcohol addiction epidemiology trends.

Other Trending Reports

Please browse through our latest blog to get more insights on Alcohol Use Disorder Treatment Landscape

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Connect with us on LinkedIn|Facebook|Twitter

Additionally, get in touch with our business executive to explore @Healthcare Due Diligence Services

Contact Us

Shruti Thakur
[email protected]
+1(919)321-6187
www.delveinsight.com

Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg

SOURCE DelveInsight Business Research LLP